Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 531 to 540 of 2194 total matches.

In Brief: Cholic Acid (Cholbam) for Bile Acid Synthesis Disorders

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
trials survived for more than 3 years.1 Some of these survivors have been treated successfully for more ...
The FDA has approved oral cholic acid (Cholbam – Retrophin) for treatment of children and adults with bile acid synthesis disorders caused by single enzyme defects and for adjunctive treatment of peroxisomal disorders such as Zellweger spectrum disorders in patients who have liver disease, steatorrhea, or complications from fat-soluble vitamin malabsorption. Patients with these rare inborn errors of bile acid metabolism cannot synthesize primary bile acids such as cholic acid, resulting in reduced bile flow, decreased absorption of fat and fat-soluble vitamins, and development of liver...
Med Lett Drugs Ther. 2016 Apr 25;58(1493):56 | Show Introduction Hide Introduction

In Brief: Jadenu - A New Formulation of Deferasirox for Iron Overload (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
) was approved in 2005 for the same indications.1 Jadenu and Exjade are the only once-daily oral formulations ...
The FDA has approved an oral tablet formulation of deferasirox (Jadenu [ jade' new] – Novartis) for once-daily treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients ≥2 years old or chronic iron overload in patients ≥10 years old with non-transfusion-dependent thalassemia syndromes. A once-daily, oral tablet for suspension formulation of deferasirox (Exjade) was approved in 2005 for the same indications.1 Jadenu and Exjade are the only once-daily oral formulations for iron chelation available in the US.No new clinical trials were required...
Med Lett Drugs Ther. 2016 Apr 25;58(1493):e56 | Show Introduction Hide Introduction

Which Oral Anticoagulant for Atrial Fibrillation?

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
by about 60%.1 If necessary, vitamin K, prothrombin complex concentrate, or fresh frozen plasma can ...
Direct-to-consumer advertisements continue to urge patients who take warfarin (Coumadin, and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral anticoagulants.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):45-6 | Show Introduction Hide Introduction

Buprenorphine Buccal Film (Belbuca) for Chronic Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
to methadone for treatment of opioid dependence.1,2 were randomized to continue taking buprenorphine ...
Belbuca (Endo), a buccal formulation of the partial opioid agonist buprenorphine, has been approved by the FDA for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Buprenorphine is also available as a transdermal patch (Butrans) and in a parenteral formulation (Buprenex, and generics) for treatment of pain. A sublingual formulation of buprenorphine and buccal and sublingual formulations containing buprenorphine and the opioid antagonist naloxone are approved for use as alternatives to methadone for treatment of opioid...
Med Lett Drugs Ther. 2016 Apr 11;58(1492):47-8 | Show Introduction Hide Introduction

Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
tolerated than either component alone.1,2 Phototherapy and systemic therapy, including biologic agents ...
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):48-9 | Show Introduction Hide Introduction

Dichlorphenamide (Keveyis) for Periodic Paralysis

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
%) benefited from acetazolamide therapy.1 MECHANISM OF ACTION — Carbonic anhydrase inhibitors are thought ...
Dichlorphenamide (Keveyis – Taro), an oral carbonic anhydrase inhibitor, has been approved by the FDA for treatment of primary hypokalemic and hyperkalemic periodic paralysis and related variants. Dichlorphenamide is the first drug to be approved in the US for this indication. It was approved as Daranide in 1958 for treatment of glaucoma, but had not been marketed since 2002.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):50 | Show Introduction Hide Introduction

Seebri Neohaler and Utibron Neohaler for COPD

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta)1 ...
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) were approved...
Med Lett Drugs Ther. 2016 Mar 28;58(1491):39-41 | Show Introduction Hide Introduction

Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
for treatment of CF in patients ≥2 years old with other mutations.1 Orkambi is the first drug to be approved ...
The FDA has approved a fixed-dose combination of lumacaftor and ivacaftor (Orkambi – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del mutation. About 50% of patients in the US with CF are homozygous for the F508del (also called Phe508del) mutation. This is the first approved indication for lumacaftor; ivacaftor is available alone as Kalydeco for treatment of CF in patients ≥2 years old with other mutations. Orkambi is the first drug to be approved in the US for treatment of patients with the F508del...
Med Lett Drugs Ther. 2016 Mar 28;58(1491):41-2 | Show Introduction Hide Introduction

Cobimetinib (Cotellic) for Metastatic Melanoma

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
-positive unresectable or metastatic melanoma.1,2 Adding the MEK inhibitor trametinib (Mekinist) improved overall ...
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib (Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Med Lett Drugs Ther. 2016 Mar 28;58(1491):43-4 | Show Introduction Hide Introduction

A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks ...
The FDA has approved Ruconest (Salix), a recombinant analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks in patients with hereditary angioedema (HAE).
Med Lett Drugs Ther. 2016 Mar 28;58(1491):e44-45 | Show Introduction Hide Introduction